CN116370377A - 一种膏霜及其制备方法和应用 - Google Patents
一种膏霜及其制备方法和应用 Download PDFInfo
- Publication number
- CN116370377A CN116370377A CN202310306195.1A CN202310306195A CN116370377A CN 116370377 A CN116370377 A CN 116370377A CN 202310306195 A CN202310306195 A CN 202310306195A CN 116370377 A CN116370377 A CN 116370377A
- Authority
- CN
- China
- Prior art keywords
- parts
- extract
- cream
- stirring
- chitosan
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006071 cream Substances 0.000 title claims abstract description 50
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000000284 extract Substances 0.000 claims abstract description 90
- 206010000496 acne Diseases 0.000 claims abstract description 47
- 208000002874 Acne Vulgaris Diseases 0.000 claims abstract description 45
- 229920001661 Chitosan Polymers 0.000 claims abstract description 42
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 32
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 17
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 17
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 17
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 17
- 229940116229 borneol Drugs 0.000 claims abstract description 17
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 17
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 17
- 229940041616 menthol Drugs 0.000 claims abstract description 17
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 17
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 17
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 16
- 229960000458 allantoin Drugs 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 16
- 208000024891 symptom Diseases 0.000 claims abstract description 14
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 12
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims abstract description 11
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 10
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims abstract description 9
- 244000197975 Solidago virgaurea Species 0.000 claims abstract description 6
- 235000000914 Solidago virgaurea Nutrition 0.000 claims abstract description 6
- 238000003756 stirring Methods 0.000 claims description 45
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 43
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 30
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 239000008367 deionised water Substances 0.000 claims description 23
- 229910021641 deionized water Inorganic materials 0.000 claims description 23
- 238000010438 heat treatment Methods 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- 239000004166 Lanolin Substances 0.000 claims description 15
- 235000021355 Stearic acid Nutrition 0.000 claims description 15
- 229940075507 glyceryl monostearate Drugs 0.000 claims description 15
- 229940039717 lanolin Drugs 0.000 claims description 15
- 235000019388 lanolin Nutrition 0.000 claims description 15
- 229940057995 liquid paraffin Drugs 0.000 claims description 15
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 claims description 15
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 15
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 15
- 239000008117 stearic acid Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 229960004274 stearic acid Drugs 0.000 claims description 13
- 241000607059 Solidago Species 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 239000005457 ice water Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims description 10
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 8
- 239000000047 product Substances 0.000 claims description 8
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 6
- 229920003012 Hydroxypropyl distarch phosphate Polymers 0.000 claims description 6
- 239000001310 hydroxy propyl distarch phosphate Substances 0.000 claims description 6
- 235000013825 hydroxy propyl distarch phosphate Nutrition 0.000 claims description 6
- DVROLKBAWTYHHD-UHFFFAOYSA-N hydroxy propyl distarch phosphate Chemical compound OC1C(O)C(OC)OC(CO)C1OC(O)CCOC1C(OC2C(C(O)C(OC3C(C(OP(O)(=O)OC4C(C(O)C(OC)OC4CO)O)C(C)OC3CO)O)OC2COC2C(C(O)C(OC)C(CO)O2)O)O)OC(CO)C(OC)C1O DVROLKBAWTYHHD-UHFFFAOYSA-N 0.000 claims description 6
- 239000000787 lecithin Substances 0.000 claims description 6
- 235000010445 lecithin Nutrition 0.000 claims description 6
- 229940067606 lecithin Drugs 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 229960001727 tretinoin Drugs 0.000 claims description 6
- 229940045110 chitosan Drugs 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 5
- 238000000265 homogenisation Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 229940095102 methyl benzoate Drugs 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 238000001556 precipitation Methods 0.000 claims description 5
- 238000001953 recrystallisation Methods 0.000 claims description 5
- 238000002390 rotary evaporation Methods 0.000 claims description 5
- 238000000967 suction filtration Methods 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 16
- 238000000605 extraction Methods 0.000 abstract description 3
- 241000196324 Embryophyta Species 0.000 abstract description 2
- 239000003242 anti bacterial agent Substances 0.000 abstract 1
- 229940088710 antibiotic agent Drugs 0.000 abstract 1
- 239000013043 chemical agent Substances 0.000 abstract 1
- 239000002085 irritant Substances 0.000 abstract 1
- 231100000021 irritant Toxicity 0.000 abstract 1
- 230000007794 irritation Effects 0.000 abstract 1
- 239000000419 plant extract Substances 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 29
- 210000003491 skin Anatomy 0.000 description 8
- 210000002374 sebum Anatomy 0.000 description 6
- 241001263604 Stellera chamaejasme Species 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 208000020154 Acnes Diseases 0.000 description 4
- 230000002910 effect on acne Effects 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 241000186427 Cutibacterium acnes Species 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 230000005906 menstruation Effects 0.000 description 3
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 3
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 229960002216 methylparaben Drugs 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 229940055019 propionibacterium acne Drugs 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- 201000009182 Chikungunya Diseases 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000110847 Kochia Species 0.000 description 2
- 206010033733 Papule Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 239000003098 androgen Substances 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000003712 anti-aging effect Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 210000001732 sebaceous gland Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000982713 Euphorbia fischeriana Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- NEAPKZHDYMQZCB-UHFFFAOYSA-N N-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]ethyl]-2-oxo-3H-1,3-benzoxazole-6-carboxamide Chemical compound C1CN(CCN1CCNC(=O)C2=CC3=C(C=C2)NC(=O)O3)C4=CN=C(N=C4)NC5CC6=CC=CC=C6C5 NEAPKZHDYMQZCB-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006196 deacetylation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- -1 i.e. Polymers 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036619 pore blockages Effects 0.000 description 1
- 230000004800 psychological effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000033785 sebaceous gland development Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000000192 social effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/736—Chitin; Chitosan; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于天然植物提取类护肤品领域,公开了一种膏霜及其制备方法和应用,所述膏霜的有效成分由以下重量份数的原料组成:金露梅提取物15‑20份、地肤子提取物10‑20份、狼毒提取物5‑10份、一枝黄花提取物3‑6份、改性壳聚糖3‑6份、透明质酸钠3‑5份、冰片2‑4份、尿囊素2‑3份、薄荷脑1‑2份、生育酚醋酸酯0.5‑1份、尼泊金甲酯0.5‑1份;本发明将金露梅提取物、地肤子提取物、狼毒提取物、一枝黄花提取物配伍使用,发现其对预防和改善女性月经前痤疮症状有较好的效果,并且本发明的主要有效成分为天然植物提取物,刺激性小,不含抗生素和刺激性化学药剂,具有良好的产业前景。
Description
技术领域
本发明属于天然植物提取类护肤品领域,具体公开了一种针对月经期痤疮具有治疗效果的膏霜及其制备方法和应用。
背景技术
痤疮是毛囊皮脂腺单位的一种慢性炎症性皮肤病,主要好发于青少年,对青少年的心理和社交影响很大,但青春期后往往能自然减轻或痊愈。临床表现以好发于面部的粉刺、丘疹、脓疱、结节等多形性皮损为特点。痤疮的发生主要与皮脂分泌过多、毛囊皮脂腺导管堵塞、细菌感染和炎症反应等因素密切相关。进入青春期后人体内雄激素特别是睾酮的水平迅速升高,促进皮脂腺发育并产生大量皮脂。同时毛囊皮脂腺导管的角化异常造成导管堵塞,皮脂排出障碍,形成角质栓即微粉刺。毛囊中多种微生物尤其是痤疮丙酸杆菌大量繁殖,痤疮丙酸杆菌产生的脂酶分解皮脂生成游离脂肪酸,同时趋化炎症细胞和介质,最终诱导并加重炎症反应。痤疮主要分为以下几类:
1、寻常性痤疮、多见于青年,好发于面颊、前额、胸背等皮脂腺较丰富部位。初起可见毛囊口处丘疹,并可挤出淡黄色脂栓,即所谓的粉刺。如毛囊口开放,脂栓因氧化及粉尘所染而呈黑色,称为黑头粉刺。2、暴发性痤疮:指患者病情突然加重,出现多发性、炎症性、毛囊性的丘疹、脓疱、溃疡、血痂,皮疹可融合成大片,并出现发热、关节痛、贫血等全身症状;3、月经前痤疮:来月经前一段时间雄性激素水平增高,或者雄性激素与雌性激素的比例相对增高,皮脂腺增大,皮脂分泌增多,导致皮脂淤积、痤疮丙酸杆菌生长,出现月经前痤疮,月经期后逐渐好转;4、化妆品痤疮:化妆品痤疮是外用油性或者粉质的劣质护肤品导致毛孔堵塞,引起炎症;5、药物性痤疮:药物性痤疮和服用某些药物有关,最常见的是糖皮质激素,还有雄激素、靶向药物等,这种类型的痤疮以炎性皮损为主要表现。
目前对痤疮具有治疗作用的膏霜往往含有大量的西药成分,比如维A酸类、过氧化苯甲酰等药物,在治疗痤疮的同时,也会发生过敏或者皮肤屏障受损等副作用。并且这类膏霜往往对于寻常性痤疮有较好效果,而对于月经前痤疮这种受激素影响较大的痤疮疗效较差,因此有必要设计一种针对月经前痤疮的膏霜护肤产品,特别是副作用较小的中药类膏霜产品。
发明内容
本发明的目的是提供一种膏霜,用以预防和改善女性月经前痤疮症状。
为实现上述目的,本发明采用如下技术方案:
一种膏霜,由有效成分和辅料组成,所述有效成分由以下重量份数的原料组成:
金露梅提取物15-20份、地肤子提取物10-20份、狼毒提取物5-10份、一枝黄花提取物3-6份、改性壳聚糖3-6份、透明质酸钠3-5份、冰片2-4份、尿囊素2-3份、薄荷脑1-2份、生育酚醋酸酯0.5-1份、尼泊金甲酯0.5-1份;
所述辅料由以下重量份数的原料组成:
液体石蜡20-40份、甘油15-20份、硬脂酸14-18份、单硬脂酸甘油酯5-10份、羊毛脂4-6份、香精1-2份、去离子水50-60份。
上述方案中,金露梅提取物具有增强毛细血管收缩,清热效果;地肤子提取物具有清热利湿,祛风止痒的作用;狼毒提取物具有散结,杀虫的功效;一枝黄花提取物和生育酚醋酸酯具有抗炎、抗氧化、抗衰老的作用,透明质酸钠可以增加皮肤保湿功能,而冰片常用于疮疡肿痛,溃后不敛,具有很强的收敛性质,尿囊素具有促进细胞生长,加快伤口愈合,软化角质蛋白等生理功能;而薄荷脑具有清凉止痒作用;上述各种成分共同作用,保持皮肤湿润,抗皱,缓解过敏以及痤疮症状。
进一步的,上述一种膏霜,所述金露梅提取物由以下步骤制备而成:
将金露梅新鲜叶片,榨汁后将汁水经过45μm滤膜过滤,滤液经旋蒸蒸发进行浓缩,得棕色浓缩液,再经过干燥得到棕色粉末,为所述金露梅提取物。优选的,选择小叶金露梅。
进一步的,上述一种膏霜,所述改性壳聚糖由以下步骤制备:
按重量份数计,将10份壳聚糖原料加入10-20份质量分数15%的醋酸溶液中,冰水浴,控制反应温度在0~5℃;在搅拌的状态下加入2-4份卵磷脂和1-2份羟丙基二淀粉磷酸酯;滴加完毕后撤去冰水浴,在30-40℃下持续搅拌反应4-8h;经静置、沉淀、抽滤、干燥、重结晶得到改性壳聚糖。壳聚糖是甲壳素N-脱乙酰基的产物,甲壳素(几丁质)、壳聚糖、纤维素三者具有相近的化学结构,纤维素在C2位上是羟基,甲壳素、壳聚糖在C2位上分别被一个乙酰氨基和氨基所代替,甲壳素和壳聚糖具有生物降解性、细胞亲和性和生物效应等许多独特的性质,尤其是含有游离氨基的壳聚糖,是天然多糖中唯一的碱性多糖。经过改性之后,连接有卵磷脂和羟丙基二淀粉磷酸酯上的基团,两亲性更好,更能促进有效成分进入皮肤之中。
进一步的,上述一种膏霜,包括以下步骤:
步骤S1,将液体石蜡、硬脂酸、单硬脂酸甘油酯、羊毛脂加入到油相容器中,加热,至完全溶解,搅拌均匀;
步骤S2,将一部分去离子水加入到水相容器A中,加入金露梅提取物、地肤子提取物、狼毒提取物、一枝黄花提取物,加热,搅拌至完全溶解,再加入甘油搅拌均匀;
步骤S3,将剩余的去离子水加入到另一水相容器B中,加入壳聚糖、透明质酸钠、冰片、尿囊素、薄荷脑、机械搅拌至完全溶解;
步骤S4,于搅拌状态下将油相容器中的液体加入到水相容器A中,再依次加入水相容器B中的液体和生育酚醋酸酯,继续搅拌;
步骤S5,将步骤S4得到的混合物进行均质;
步骤S6,向均质后的混合物中加入尼泊金甲酯和香精,继续搅拌,出料,得到所述膏霜。
优选的,所述步骤S1中,加热温度为80-90℃。
优选的,所述步骤S2中,加热温度为60-70℃。
优选的,所述步骤S2中加入3/5的去离子水,步骤S3中加入剩余的2/5的去离子水。
优选的,所述步骤S3中,完全溶解后于70-80℃保温。
优选的,所述步骤S5中,降温至45-55℃,均质5-10min。
进一步的,在制备预防或改善月经前痤疮症状的护肤品中的用途。
进一步的,一种护肤组合物,含有上述膏霜中的有效成分和维A酸。
本发明具有以下有益效果:
金露梅提取物具有增强毛细血管收缩,清热效果;地肤子提取物具有清热利湿,祛风止痒的作用;狼毒提取物具有散结,杀虫的功效;一枝黄花提取物和生育酚醋酸酯具有抗炎、抗氧化、抗衰老的作用;本发明将上述有效物质综合使用,发现其具有较好的改善月经前痤疮症状的作用,进一步的,本发明还发现,将本发明中制备的膏霜和维A酸同时制备成组合物,能够同时治疗寻常性痤疮和月经前痤疮,非常适合青中年女性患者使用。
附图说明
附图1为实施例2以及对比例1-6对于月经前痤疮症状的改善情况比较;
附图2为实施例2以及对比例1-6对于月经前痤疮症状的改善率比较。
具体实施方式
下面对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其它实施例,都属于本发明保护的范围。
本发明实施例中使用的试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规试剂产品。
地肤子提取物购自湖北科沃德化工有限公司货号kds321215纯度99%。
狼毒提取物购自陕西新天域生物科技有限公司,1公斤/铝箔袋,提取部位根部,纯度99%。
一枝黄花提取物购自山东亚图生物科技有限公司,CAS号112509-54-3,纯度99%。
实施例1
一种膏霜,由有效成分和辅料组成,所述有效成分由以下的原料组成:
金露梅提取物15g、地肤子提取物10g、狼毒提取物5g、一枝黄花提取物3g、改性壳聚糖3g、透明质酸钠3g、冰片2g、尿囊素2g、薄荷脑1g、生育酚醋酸酯0.5g、尼泊金甲酯0.5g;
所述辅料由以下的原料组成:
液体石蜡20g、甘油15g、硬脂酸14g、单硬脂酸甘油酯5g、羊毛脂4g、香精1g、去离子水50g。
所述金露梅提取物由以下步骤制备而成:
将金露梅新鲜叶片,榨汁后将汁水经过45μm滤膜过滤,滤液经旋蒸蒸发进行浓缩,得棕色浓缩液,再经过干燥得到棕色粉末,为所述金露梅提取物。
所述改性壳聚糖由以下步骤制备:
将10g壳聚糖原料加入15g质量分数15%的醋酸溶液中,冰水浴,控制反应温度在0~5℃;在搅拌的状态下加入3g卵磷脂和1.5g羟丙基二淀粉磷酸酯;滴加完毕后撤去冰水浴,在30-40℃下持续搅拌反应4-8h;经静置、沉淀、抽滤、干燥、重结晶得到改性壳聚糖。
上述膏霜的制备方法,包括以下步骤:
步骤S1,将液体石蜡、硬脂酸、单硬脂酸甘油酯、羊毛脂加入到油相容器中,加热,至完全溶解,搅拌均匀;
步骤S2,将一部分去离子水加入到水相容器A中,加入金露梅提取物、地肤子提取物、狼毒提取物、一枝黄花提取物,加热,搅拌至完全溶解,再加入甘油搅拌均匀;
步骤S3,将剩余的去离子水加入到另一水相容器B中,加入壳聚糖、透明质酸钠、冰片、尿囊素、薄荷脑、机械搅拌至完全溶解;
步骤S4,于搅拌状态下将油相容器中的液体加入到水相容器A中,再依次加入水相容器B中的液体和生育酚醋酸酯,继续搅拌;
步骤S5,将步骤S4得到的混合物进行均质;
步骤S6,向均质后的混合物中加入尼泊金甲酯和香精,继续搅拌,出料,得到所述膏霜;
所述步骤S1中,加热温度为80-90℃;
所述步骤S2中,加热温度为60-70℃;
所述步骤S2中加入3/5的去离子水,步骤S3中加入剩余的2/5的去离子水;
所述步骤S3中,完全溶解后于70-80℃保温;
所述步骤S5中,降温至45-55℃,均质5-10min。
实施例2
一种膏霜,由有效成分和辅料组成,所述有效成分由以下的原料组成:
金露梅提取物18g、地肤子提取物15g、狼毒提取物7g、一枝黄花提取物4.5g、改性壳聚糖4.5g、透明质酸钠4g、冰片3g、尿囊素2.5g、薄荷脑1.5g、生育酚醋酸酯0.8g、尼泊金甲酯0.8g;
所述辅料由以下重量g数的原料组成:
液体石蜡30g、甘油18g、硬脂酸16g、单硬脂酸甘油酯8g、羊毛脂5g、香精1.5g、去离子水55g。
所述金露梅提取物由以下步骤制备而成:
将金露梅新鲜叶片,榨汁后将汁水经过45μm滤膜过滤,滤液经旋蒸蒸发进行浓缩,得棕色浓缩液,再经过干燥得到棕色粉末,为所述金露梅提取物。
所述改性壳聚糖由以下步骤制备:
将10g壳聚糖原料加入15g质量分数15%的醋酸溶液中,冰水浴,控制反应温度在0~5℃;在搅拌的状态下加入3g卵磷脂和1.5g羟丙基二淀粉磷酸酯;滴加完毕后撤去冰水浴,在30-40℃下持续搅拌反应4-8h;经静置、沉淀、抽滤、干燥、重结晶得到改性壳聚糖。
上述膏霜的制备方法,包括以下步骤:
步骤S1,将液体石蜡、硬脂酸、单硬脂酸甘油酯、羊毛脂加入到油相容器中,加热,至完全溶解,搅拌均匀;
步骤S2,将一部分去离子水加入到水相容器A中,加入金露梅提取物、地肤子提取物、狼毒提取物、一枝黄花提取物,加热,搅拌至完全溶解,再加入甘油搅拌均匀;
步骤S3,将剩余的去离子水加入到另一水相容器B中,加入壳聚糖、透明质酸钠、冰片、尿囊素、薄荷脑、机械搅拌至完全溶解;
步骤S4,于搅拌状态下将油相容器中的液体加入到水相容器A中,再依次加入水相容器B中的液体和生育酚醋酸酯,继续搅拌;
步骤S5,将步骤S4得到的混合物进行均质;
步骤S6,向均质后的混合物中加入尼泊金甲酯和香精,继续搅拌,出料,得到所述膏霜;
所述步骤S1中,加热温度为80-90℃;
所述步骤S2中,加热温度为60-70℃;
所述步骤S2中加入3/5的去离子水,步骤S3中加入剩余的2/5的去离子水;
所述步骤S3中,完全溶解后于70-80℃保温;
所述步骤S5中,降温至45-55℃,均质5-10min。。
实施例3
一种膏霜,由有效成分和辅料组成,所述有效成分由以下的原料组成:
金露梅提取物20g、地肤子提取物20g、狼毒提取物10g、一枝黄花提取物6g、改性壳聚糖6g、透明质酸钠5g、冰片4g、尿囊素3g、薄荷脑2g、生育酚醋酸酯1g、尼泊金甲酯1g;
所述辅料由以下重量g数的原料组成:
液体石蜡40g、甘油20g、硬脂酸18g、单硬脂酸甘油酯10g、羊毛脂6g、香精2g、去离子水60g。
所述金露梅提取物由以下步骤制备而成:
将金露梅新鲜叶片,榨汁后将汁水经过45μm滤膜过滤,滤液经旋蒸蒸发进行浓缩,得棕色浓缩液,再经过干燥得到棕色粉末,为所述金露梅提取物。
所述改性壳聚糖由以下步骤制备:
将10g壳聚糖原料加入15g质量分数15%的醋酸溶液中,冰水浴,控制反应温度在0~5℃;在搅拌的状态下加入3g卵磷脂和1.5g羟丙基二淀粉磷酸酯;滴加完毕后撤去冰水浴,在30-40℃下持续搅拌反应4-8h;经静置、沉淀、抽滤、干燥、重结晶得到改性壳聚糖。
上述膏霜的制备方法,包括以下步骤:
步骤S1,将液体石蜡、硬脂酸、单硬脂酸甘油酯、羊毛脂加入到油相容器中,加热,至完全溶解,搅拌均匀;
步骤S2,将一部分去离子水加入到水相容器A中,加入金露梅提取物、地肤子提取物、狼毒提取物、一枝黄花提取物,加热,搅拌至完全溶解,再加入甘油搅拌均匀;
步骤S3,将剩余的去离子水加入到另一水相容器B中,加入壳聚糖、透明质酸钠、冰片、尿囊素、薄荷脑、机械搅拌至完全溶解;
步骤S4,于搅拌状态下将油相容器中的液体加入到水相容器A中,再依次加入水相容器B中的液体和生育酚醋酸酯,继续搅拌;
步骤S5,将步骤S4得到的混合物进行均质;
步骤S6,向均质后的混合物中加入尼泊金甲酯和香精,继续搅拌,出料,得到所述膏霜;
所述步骤S1中,加热温度为80-90℃;
所述步骤S2中,加热温度为60-70℃;
所述步骤S2中加入3/5的去离子水,步骤S3中加入剩余的2/5的去离子水;
所述步骤S3中,完全溶解后于70-80℃保温;
所述步骤S5中,降温至45-55℃,均质5-10min。
对比例1
本对比例使用普通壳聚糖,脱乙酰度90%,CAS号:9012-76-4,分子量为150000,不使用改性壳聚糖,即其他实施例1-3中改性前的壳聚糖,其他同实施例2。
对比例2
本对比例不含有金露梅提取物,其他同实施例2。
对比例3
本对比例不含有地肤子提取物,其他同实施例2。
对比例4
本对比例不含有狼毒提取物,其他同实施例2。
对比例5
本对比例不含有一枝黄花提取物,其他同实施例2。
对比例6
市售维a酸乳膏(0.05%)。
测试例1
本测试例主要测试实施例1-3制备的软膏的理化性质。
1.将实例1-3制备的膏霜置于50℃恒温箱中48h,发现制备的乳膏保持均一、稳定,无分层现象,说明本发明制备的膏霜具有热稳定性。
2.将实例1-3制备的膏霜置于离心管中,于3000rpm条件下离心30min,发现制备的乳膏保持均一、稳定,无分层现象,说明本发明制备的膏霜具有较好的稳定性。
测试例2
本测试例测试实施例2以及对比例1-6对于寻常痤疮症状的改善。
选取210名诊断为寻常痤疮的女性受试志愿者,年龄20-40岁,平均随机分为7组,每组30名。每天早晚使用2次,每次0.1g,连续使用30天;对比使用前后痤疮数量、大小、颜色,
判断标准:
无效:痤疮无明显改善情况,甚至加重;
稍微有效:痤疮数量无明显变化,但体积变小、颜色变浅;
有效:痤疮数量明显减少,颜色变淡,基本消退。
结果见表1所示。
表1寻常痤疮的治疗效果
稍微有效 | 有效 | 无效 | 有效率(%) | |
实施例2 | 10 | 13 | 7 | 76 |
对比例1 | 10 | 9 | 11 | 63 |
对比例2 | 9 | 8 | 13 | 56 |
对比例3 | 8 | 8 | 14 | 53 |
对比例4 | 9 | 9 | 12 | 60 |
对比例5 | 11 | 9 | 10 | 66 |
对比例6 | 5 | 21 | 4 | 86 |
上述结果表明,本发明对于寻常痤疮有一定疗效,但是效果较市售的维a酸乳膏(0.05%)稍差,但是本发明的优点在于基本不含有西药,绿色天然。
测试例2
本测试例测试实施例2以及对比例1-6对于月经前痤疮症状的改善。
选取140名诊断为月经前痤疮的女性受试志愿者,年龄20-40岁,平均随机分为7组,每组20名。每天早晚使用2次,每次0.1g,连续使用45天;对比使用前后两次月经痤疮数量、大小、颜色。结果见表2所示。
表2对于月经前痤疮症状的改善情况
稍微有效 | 有效 | 无效 | 有效率(%) | |
实施例2 | 4 | 15 | 1 | 95 |
对比例1 | 6 | 12 | 2 | 90 |
对比例2 | 8 | 8 | 4 | 80 |
对比例3 | 7 | 8 | 5 | 75 |
对比例4 | 8 | 7 | 5 | 75 |
对比例5 | 7 | 7 | 6 | 70 |
对比例6 | 8 | 4 | 8 | 60 |
由上表数据,以及图1和图2可看出,具备金露梅提取物、地肤子提取物、狼毒提取物和一枝黄花提取物的实施例2具有最佳的有效率,而将其中的改性壳聚糖改为壳聚糖后,有效率下降,可推断改性壳聚糖对于疗效也有增加作用,再从对比例2-5可以看出,分别除去金露梅提取物、地肤子提取物、狼毒提取物和一枝黄花提取物,均会引起有效率较大的下降,只有组合使用才能达到最佳效果,从对比例6可以看出,维A酸软膏虽然对于寻常痤疮的疗效好于本膏霜,但是对于月经前痤疮症状的改善有效率大幅度的低于本发明所述的膏霜。从这一点启发我们,可以将本发明所述的膏霜与维A酸联用,用于治疗合并有月经前痤疮症状的寻常痤疮患者,具有良好的产业前景。
以上显示和描述了本发明的基本原理、主要特征和优点。本行业的技术人员应该了解,上述实施例不以任何形式限制本发明,凡采用等同替换或等效变换的方式所获得的技术方案,均落在本发明的保护范围内。
Claims (10)
1.一种膏霜,由有效成分和辅料组成,其特征在于,所述有效成分由以下重量份数的原料组成:
金露梅提取物15-20份、地肤子提取物10-20份、狼毒提取物5-10份、一枝黄花提取物3-6份、改性壳聚糖3-6份、透明质酸钠3-5份、冰片2-4份、尿囊素2-3份、薄荷脑1-2份、生育酚醋酸酯0.5-1份、尼泊金甲酯0.5-1份;
所述辅料由以下重量份数的原料组成:
液体石蜡20-40份、甘油15-20份、硬脂酸14-18份、单硬脂酸甘油酯5-10份、羊毛脂4-6份、香精1-2份、去离子水50-60份。
2.根据权利要求1所述的一种膏霜,其特征在于,所述金露梅提取物由以下步骤制备而成:
将金露梅新鲜叶片,榨汁后将汁水经过45μm滤膜过滤,滤液经旋蒸蒸发进行浓缩,得棕色浓缩液,再经过干燥得到棕色粉末,为所述金露梅提取物。
3.根据权利要求1所述的一种膏霜,其特征在于,所述改性壳聚糖由以下步骤制备:
按重量份数计,将10份壳聚糖原料加入10-20份质量分数15%的醋酸溶液中,冰水浴,控制反应温度在0~5℃;在搅拌的状态下加入2-4份卵磷脂和1-2份羟丙基二淀粉磷酸酯;滴加完毕后撤去冰水浴,在30-40℃下持续搅拌反应4-8h;经静置、沉淀、抽滤、干燥、重结晶得到改性壳聚糖。
4.如权利要求1-3任一项所述的膏霜的制备方法,其特征在于,包括以下步骤:
步骤S1,将液体石蜡、硬脂酸、单硬脂酸甘油酯、羊毛脂加入到油相容器中,加热,至完全溶解,搅拌均匀;
步骤S2,将一部分去离子水加入到水相容器A中,加入金露梅提取物、地肤子提取物、狼毒提取物、一枝黄花提取物,加热,搅拌至完全溶解,再加入甘油搅拌均匀;
步骤S3,将剩余的去离子水加入到另一水相容器B中,加入壳聚糖、透明质酸钠、冰片、尿囊素、薄荷脑、机械搅拌至完全溶解;
步骤S4,于搅拌状态下将油相容器中的液体加入到水相容器A中,再依次加入水相容器B中的液体和生育酚醋酸酯,继续搅拌;
步骤S5,将步骤S4得到的混合物进行均质;
步骤S6,向均质后的混合物中加入尼泊金甲酯和香精,继续搅拌,出料,得到所述膏霜。
5.根据权利要求4所述的膏霜的制备方法,其特征在于:所述步骤S1中,加热温度为80-90℃。
6.根据权利要求4所述的膏霜的制备方法,其特征在于:所述步骤S2中,加热温度为60-70℃。
7.根据权利要求4所述的膏霜的制备方法,其特征在于:所述步骤S3中,完全溶解后于70-80℃保温。
8.根据权利要求4所述的膏霜的制备方法,其特征在于:所述步骤S5中,降温至45-55℃,均质5-10min。
9.如权利要求1-3任一项所述的膏霜在制备预防或改善月经前痤疮症状的护肤品中的用途。
10.一种护肤组合物,其特征在于,含有如权利要求1-3任一项所述的膏霜中的有效成分和维A酸。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310306195.1A CN116370377A (zh) | 2023-03-27 | 2023-03-27 | 一种膏霜及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310306195.1A CN116370377A (zh) | 2023-03-27 | 2023-03-27 | 一种膏霜及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN116370377A true CN116370377A (zh) | 2023-07-04 |
Family
ID=86970597
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310306195.1A Pending CN116370377A (zh) | 2023-03-27 | 2023-03-27 | 一种膏霜及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116370377A (zh) |
-
2023
- 2023-03-27 CN CN202310306195.1A patent/CN116370377A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6530817B2 (ja) | ニキビ除去スキンケア製品とその製造方法 | |
KR102033089B1 (ko) | 항균, 항염증, 피지감소, 각질박리 및 피부진정용 조성물 | |
CN114306432B (zh) | 一种具有防脱生发功能的植物外泌体组合物及其制备方法 | |
CN106075399A (zh) | 用于激素性皮炎的组合物,制剂及制备方法和应用 | |
EP3342419B1 (en) | Acne-removing traditional chinese medicine composition and preparation method thereof | |
CN103393801B (zh) | 具有祛痤疮功效的中药复方提取物及其制备方法与应用 | |
JPH0374649B2 (zh) | ||
CN105434195B (zh) | 一种具有祛痘且抑制痘痕生成功能的组合物及其应用 | |
KR101827771B1 (ko) | 닥나무 추출물을 함유하는 여드름 개선용 화장료 조성물 | |
CN113797143A (zh) | 一种菠萝蛋白酶祛痘精华液及其制备方法 | |
AU584965B2 (en) | Skin care compositions having keratolytic and antiinflammatory activity | |
WO2022047862A1 (zh) | 一种生发中药组合物及其制备方法和应用 | |
CN116370377A (zh) | 一种膏霜及其制备方法和应用 | |
CN115177975B (zh) | 一种通过超分子工艺从药用层孔菌中提取多糖类、多酚类及三萜类成分的方法 | |
KR101852510B1 (ko) | 닥나무 추출물을 함유하는 피부의 지질 생성 억제 및 피지 분비 감소용 화장료 조성물 | |
CN111419940B (zh) | 一种祛痘的中草药组合物 | |
CN110151657B (zh) | 一种含有垂盆草提取物的祛痘凝胶及其制备方法 | |
CN108379339B (zh) | 一种多靶点抑菌祛痘凝胶的制备方法 | |
CN111700972A (zh) | 一种祛痘中药组合物及其制备方法 | |
WO2020022991A2 (en) | Topical compositions for stretch marks on the skin | |
CN110664668A (zh) | 一种含水溶性大麻二酚的祛痘护肤凝胶及其制备方法 | |
CN108403621B (zh) | 一种多靶点抑菌祛痘凝胶及其制备方法 | |
JP3826698B2 (ja) | 微生物性リパーゼ阻害剤、及びこれを含有するニキビ用皮膚外用剤並びにフケ用皮膚外用剤 | |
CN108653077A (zh) | 一种草本祛痘膏及其制备方法 | |
CN107669594A (zh) | 一种含芦荟油的化妆品组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |